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ATP-binding cassette (ABC) transporters, in particular P-glycoprotein (encoded by ABCB1), are important and selective elements
of the blood-brain barrier (BBB), and they actively contribute to brain homeostasis. Changes in ABCB1 expression and/or function
at the BBBmay not only alter the expression and function of other molecules at the BBB but also affect brain environment. Over the
last decade, a number of reports have shown that ABCB1 actively mediates the transport of beta amyloid (Aβ) peptide. This finding
has opened up an entirely new line of research in the field of Alzheimer’s disease (AD). Indeed, despite intense research efforts, AD
remains an unsolved pathology and effective therapies are still unavailable. Here, we review the crucial role of ABCB1 in the Aβ
transport and how oxidative stress may interfere with this process. A detailed understanding of ABCB1 regulation can provide
the basis for improved neuroprotection in AD and also enhanced therapeutic drug delivery to the brain.
1. Introduction
The rise in life expectancy, with the relative aging of the
population, involves serious demographic, ethical, social,
economic, and medical problems. In particular, the incidence
of neurodegenerative diseases has increased considerably by
ten or fifteen years to this part. Common to all of the neuro-
degenerative disorders is the irreversible degeneration of dis-
tinct subsets of neurons, the accumulation of aggregated
peptides, and the imbalance of cellular oxidative state.
Alzheimer’s disease (AD) is the most common cause of
dementia and one of the most important causes of morbidity
and mortality among the aging population. The appearance
of beta amyloid (Aβ)plaques in the extracellular compartment
of the brain parenchyma is a hallmark of AD, and biochemical
and genetic findings highlight the crucial role of the Aβ
peptide in the pathogenesis ofAD[1]. In addition to the recog-
nized pathological signs of senile plaques and neurofibrillary
tangles, the presence of extensive oxidative stress (OS) is a
contributing factor in the progression of AD. The accumula-
tion of free radical damage and alterations in the activities of
antioxidant enzymes are also present in AD patients [2].
However, the exact mechanisms by which the redox balance
is altered and the sources of free radicals in the AD brain are
still unknown. It has been demonstrated that Aβ is capable
of promoting the formation ofROS through amechanism that
involves the PI3K/Akt/GSK3 and MAPK/ERK1/2 pathways
[3] and that OS may increase Aβ production and aggregation
as well facilitate tau phosphorylation, forming a vicious cycle
that promotes the progression of AD [4].
The question to ask is why the Aβ peptide accumulates in
the brain. There are two possible explanations: (i) the over-
production of Aβ in the brain and (ii) the reduced clearance
of Aβ from the brain [5, 6]. Only familial AD (5% of cases) is
due to the overproduction of Aβ because of mutations in the
amyloid precursor protein (APP) gene or in the APP process-
ing enzymes [7, 8], while the greater part (95%) of the so-
called sporadic AD cases are probably caused by dysfunc-
tions in Aβ aggregation, degradation, and removal [5, 9]. It
has been proposed that the underlying cause of Aβ accumu-
lation in AD is a reduced clearance of Aβ from the brain via
the blood-brain barrier (BBB) [10, 11].
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ATP-binding cassette (ABC) transporters are multido-
main integral membrane proteins that use the energy of ATP
hydrolysis to translocate solutes across cellular membranes
in all mammalian species [12]. In the last decade, a number
of reports have shown that members of the ABC superfamily
of membrane proteins, in particular P-glycoprotein (encoded
by ABCB1), actively mediate the transport of Aβ [13]. Cirrito
et al. [14] demonstrated that the deficiency of ABCB1 at the
BBB increasedAβdeposition in anADmousemodel, suggest-
ing that Aβ is transported out of the brain or periarterial
interstitial fluid through this transport system.
Although many studies on ABCB1 and AD are present in
the literature, the link between OS and ABC membrane
transport systems, during aging and in OS-related diseases,
as AD, is still unclear, thus providing an urgent need for a
deeper understanding of mechanisms through which such
processes and diseases develop. In this review, we discuss
the possible role of ABCB1 and OS in AD and consider
how a fuller understanding of these aspects might promote
the development of more effective treatment strategies.
2. Blood-Brain Barrier and Oxidative Stress
In the human body, the brain represents the most sensitive
organ to OS, not only because its own proper function
requires the precise control of the extracellular environment
but also because of the huge demand for nutrients by the
brain itself. Indeed, the oxygen requirements of the brain
tissue accounts for approximately 20% of the total human
oxygen consumption [15]. The BBB is an essential biochem-
ical and physical barrier that separates the central nervous
system (CNS) from the bloodstream and plays a funda-
mental role in the balance of the brain microenvironment.
Indeed, it maintains the ion balance and the low gradient
of excitatory neurotransmitters, regulates the transport of
specific nutrients, and limits the entry of toxic substances
both endogenous and exogenous [13]. This is essential
for a reliable synaptic transmission and an effective neu-
roregulation activity. In this view, it promotes the longev-
ity of the SNC and prevents premature death and cellular
neurodegeneration [16].
This barrier is mainly formed by a monolayer of tightly
junctioned endothelial cells. Anyway, this is not enough to
form a functionally BBB per se, which requires the presence
of interaction with adjacent glial cells as well as neurons,
pericytes, and collagen extracellular matrix [17, 18]. This
intricate relationship between both vascular and neuronal
cells is called implied neurovascular unit (NVU). The NVU
avoids the entry of compounds from the circulating blood
to the brain via paracellular or transcellular diffusion. For this
reason, the brain homeostasis is maintained through specific
transporters or passive diffusion mechanisms [19]. In fact,
oxygen, carbon dioxide, glucose, nucleosides, vitamins, and
part of liposoluble drugs can reach the SNC, but it has been
reported that the BBB is responsible for blocking the delivery
of more than 98% of drugs [20–22].
Several neurodegenerative diseases are characterized by
increased inflammation. Indeed, neuroinflammation exacer-
bates the pathology by generating inflammatory mediators,
as well as by activating microglia, and by the production of
reactive oxygen species (ROS). All together, these events
contribute to spread OS [23, 24]. The resulting condition is
that the BBB tight junctions are wrecked, causing a consistent
variation in brain microenvironment [25].
Microglia, as the first and primary active immune defense
in the CNS, express multiple subfamilies of ABC transporters
and are particularly sensitive to brain injury or disease and
switch their morphology and phenotype to an “activated”
state in response to brain insults [26, 27].
Among ROS, the superoxide anion, a by-product of
physiological processes, contribute to BBB endothelial
dysfunction [28–30]. In normal conditions, superoxide dis-
mutase (SOD) enzyme regulates biological activity of super-
oxide, but under oxidative conditions, the anion is produced
at high levels that overcome the metabolic capacity of SOD.
BBB damage can be intensified by conjugation of superoxide
and nitric oxide (NO) to form peroxynitrite, a cytotoxic and
proinflammatory molecule. Peroxynitrite causes significant
injury to microvessels through lipid peroxidation, consump-
tion of endogenous antioxidants, and induction of mitochon-
drial failure [31, 32]. Overall, OS contributes to disruption of
endothelial cell-cell interactions and to BBB injury by pro-
moting redistribution or downregulation of critical tight junc-
tion proteins such as claudin-5, occludin, zonula occludens-1,
and junctional adhesion molecule-1 [33–36].
In particular, the importance of brain-to-blood transport
of brain-derived metabolites across the BBB has gained
increasing attention as a potential mechanism in the patho-
genesis of neurodegenerative disorders.
3. ABC Transporters
The cells forming the NVU achieve the control of brain
homeostasis and microenvironment by the expression of
complex active transport systems, such as ion channels,
pumps, receptors, and transporters on the luminal or ablum-
inal side of the BBB [37]. Despite the presence of BBB, small
molecules and macromolecules could be transported into the
brain to maintain its homeostasis. There are three main
classes of BBB transporters: carrier-mediated transporters
(CMT), active efflux transporters (AET), and receptor-
mediated transporter (RMT). The CMT and AET systems
are mainly responsible for the transport of small molecules,
while the RMT systems are reserved for large molecules
and involve endocytic transport. AET transporters include
ABC family members, which form one of the largest of all
protein families and are central to many important biomed-
ical phenomena, including resistance of cancers and patho-
genic microbes to drugs [38]. In fact, ABC transport system
regulates drug bioavailability, metabolism, and distribution
in cells and in the extracellular matrix, limiting substrate
cellular influx and retention [39–42]. ABC proteins share a
common molecular structure composed by nucleotide-
binding domains, which conserved peptide motifs, and
transmembrane domains, usually composed of six trans-
membrane helices [43]. In the BBB, ABC transporters are
localized on the blood-facing plasma membrane where they
allow unidirectional transport from the cytoplasm to the
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extracellular space. This localization can be considered as a
strategy to protect the brain against the numerous lipophilic
xenobiotics which, because of their chemical structure,
should rapidly diffuse across endothelial cell membranes
[42, 44–46].
The human ABC superfamily includes 48 multidrug
transporters, belonging to one of the seven ABC A to ABC
G subfamilies. These subfamilies include the ABCA member
1 (ABCA1) that acts as cholesterol efflux regulatory protein
(CERP) and extrudes phospholipids from cell membranes
to Apolipoprotein E (ApoE); the ABCB subfamily member
1 (ABCB1), which mediates multidrug resistance (MDR);
the ABCC subfamily of multidrug resistance-associated
proteins (MRP); and the ABCG2 subfamily of the breast
cancer resistance protein (BRCP) [40]. Depending on their
subfamily, these transporters act either as “protectors” or as
“vehicle” for bioactive molecules produced by cells [45].
The first transporter to be identified and studied was the
ABCB1, a phosphorylated glycoprotein of 170 kDa usually
localized on the luminal side of the brain capillary endothelial
cells. In humans, it is coded from the mdr1 gene, of which
there are more than 50 polymorphisms at the level of single
nucleotide. Because of its highly polymorphic nature, this
gene is responsible for a strong variability in drug absorption
and tolerance [47]. Among these polymorphisms, the
rs1128503 is a nucleotide change in exon 12 (C1236T) that
does not alter the glycine at position 412, while the triallelic
rs2032582 polymorphism in exon 21 (G2677T/A) leads to
an alanine to threonine or serine amino acid substitution
(Ala893Thr/Ser). Finally, the rs1045642 synonymous poly-
morphism in exon 26 (C3435T) does not affect the leucine
at position 1145 [48]. To the best of our knowledge, the main
products of this gene are two, ABCB1 and ABCB2, but only
the first one confers multidrug resistance [49]. This is due
to the fact that ABCB2 is commonly expressed by hepato-
cytes at the canalicular side for the secretion of phosphatidyl-
choline into the bile fluid [50].
Because of the primary sequence of ABCB1, that contains
the characteristic short ATP-binding motifs and in between
an additional conserved sequence characteristic of ABC
superfamily, ABCB1 has been classified as ABC transporters.
ABCB1 is localized in both the luminal and abluminal mem-
branes of brain capillary endothelial cells to carry out its role
as “brain sentinel” [51–54]. It is still not clear if the expres-
sion of ABCB1 is only restricted to those brain blood vessels
that are part of the BBB, or if it is equally expressed in fenes-
trated capillaries of the circumventricular organs (area post-
rema in the brainstem, the subfornical organ, the median
eminence, the pineal body, the vascular organ of the lamina
terminalis, choroid plexus, and neurohypophysis) [55, 56].
Several studies have demonstrated that rat astrocytes and
microglial cultures can express multiple membrane trans-
porters including ABCB1, but in lower levels when compared
to brain endothelial cells culture [57–59]. Differently, many
studies demonstrated the expression of ABCB1 at microglia,
astrocytes, and pericytes adjacent to endothelial cells in
normal primate brains [60–62]. These authors reported that
ABCB1 was distributed along the nuclear envelope, in the
caveolae, in cytoplasmic vesicles, and in Golgi complex and
rough endoplasmic reticulum. On the other hand, numerous
studies did not detect ABCB1 in neuronal or glial cells, sug-
gesting that its expression in these cells may depend by path-
ological CNS conditions from seizures to tumors [63–67].
Besides its protective function, ABCB1 has also been
implicated in resistance to apoptosis. The programmed cell
death contributes to tissue remodeling and to elimination
of damaged cells, and through the stimulation of this path-
way, ABCB1 may affect the regenerative process in lesioned
tissue. Several mechanisms that could explain this event have
been described. First, ABCB1 might block the caspase-3 acti-
vation by inhibiting caspase-8 induction that is normally
conducted by Fas. As shown by Ruefli et al. [68], this event
needs ATP binding or hydrolysis, because mutations in the
ATP-binding regions abolished ABCB1-mediated Fas resis-
tance. Second, ABCB1 may affect the apoptosis induced by
ceramide. Indeed, when ceramide is not converted into the
nontoxic glucosylceramide, it mediates cell death. ABCB1
promotes the translocation of the nontoxic derivate from
the cytosolic to the luminal face of the Golgi and in this
way influences directly ceramide metabolism and, indirectly,
causes apoptosis resistance [69, 70].
In the beginning, this drug efflux pump was discovered
by oncologists as responsible for chemotherapy resistance,
but besides this ability, ABCB1 confers resistance to numer-
ous drugs, including immunosuppressive drugs, HIV prote-
ase inhibitors, and antibiotics [71–73].
ABCB1 function could be counteracted with competitive
inhibitors, such as verapamil and cyclosporine A, or directly
by blocking its function, as with elacridar (GF120918)
[74–78]. It has been shown that a clinically relevant oral
dose of oxytetracycline is able to saturate ABCB1 and, subse-
quently, to increase the absorption of other drugs [79].
Several side effects may be associated with the inhibition of
this transporter activity. A dramatic example is congestive
heart failure caused by a combined therapy of verapamil
and doxorubicin to inhibit ABCB1 [80]. The use of efflux
transporters inhibitors, when applied coincidently for gen-
eral treatment or to enhance CNS uptake of drugs, are better
suited to acute therapies where the aim is to reach short max-
imal concentrations, as happens in the treatment of brain
tumors, than for chronic administration where long-term
inhibition will interfere with the normal brain homeostasis.
In this context, it is also interesting to consider a recent
review by Kalvass et al. [81], in which authors discussed the
low probability of modulating transporters at the human
BBB by currently marketed drugs. The central conclusion
of their work is that, while increased CNS distribution of
efflux transport substrates has been commonly observed in
animal models and when dosed with nonmarketed inhibitors
(e.g., tariquidar) in humans, the overall clinical evidence
indicates that drug interactions at the human BBB due to
efflux transporter inhibition by marketed drugs are low in
magnitude (≤2-fold increase in brain : plasma ratio). More-
over, serious adverse CNS safety events arising from these
interactions have not been observed.
Looking at the cerebral proteopathies, a long inhibitory
treatment may lead to raised intracerebral concentrations of
a large spectrum of neurotoxic substances that enter the brain
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or are directly being produced within the brain. These
changes of the transport kinetics and the accumulation of
neurotoxins species should take in the study of the pathogen-
esis of neurodegenerative diseases, where dysfunction of
ABCB1 has been associated with Parkinson’s disease (PD),
progressive supranuclear palsy (PSP), multisystem atrophy
(MSA), and with depressive disorders [82–85].
Whereas ABCB1 has long dominated the “stage” of
transporter-related drug resistance in cancer, other ABC
transporters became clinically relevant in the 1990s. In partic-
ular, the ABCC family includes 13 related ABC transporters
that are able to transport structurally different lipophilic
anions. The most intriguing feature of ABCCs is that they
provide a transport facility for compounds (drugs, xenobi-
otics, or physiological substrates) conjugated with glutathione
(GSH), glucuronide, or sulfate. For several tissues and cell
types, the release of glutathione disulfide (GSSG) has been
reported during OS and has been proposed to be an endoge-
nous mechanism of cellular defense [86, 87]. Among ABCC
transporter subfamily, ABCC1–4 are known to be responsible
for GSH and GSSG transport [88–90]. Indeed, studies in pri-
mary cultures of rat astrocytes showed that MK571, a known
inhibitor of ABCC, blocks the transport of GSH [91]. Despite
the fundamental role of ABCC family in the detoxifying
cellular system, in this context, our attention is focalized on
the role of ABCB1 and OS in AD.
4. ABCB1 and Oxidative Stress in
Alzheimer’s Disease
Apart from the fact that ABCB1 remains one of the major
cause of chemotherapy resistance in cancer, this transport
protein play an important role as export pump of endoge-
nous compounds and exogenous toxic agents in a variety of
cells and tissues. Because of its high levels of expression at
the BBB, ABCB1 is a powerful gatekeeper to the brain. We
can affirm that ABC transporters in general, and ABCB1 in
particular, have evolved to counteract OS, indeed toxic com-
pounds generated are eliminated by ABC transporters after
they are detoxified by conjugation to GSH, glucuronide,
and sulfate. Interestingly, following organ damage or disease,
changes in the expression levels of ABC transporters have
been observed, probably to compensate the increased load
of OS products or to compensate for the loss of efflux pumps
in damaged tissues. Alteration of ABCB1 participated in
many CNS disorders, such as upregulation in epilepsy [92],
neural inflammation [93], and stroke [94]. DeMars et al.
[95] demonstrated that middle cerebral artery occlusion
increased ABCB1 in the liver in conjunction with increased
ABCB1 in the brain. Certainly, understanding mechanisms
and signals that modulate ABCB1 expression and activity at
the BBB could result in new therapeutic targets for CNS disor-
ders. Many sensors of the cellular and extracellular environ-
ment are capable of changing ABC transporter expression at
the BBB, in particular oxidative and inflammatory stress, diet,
pharmacotherapy, and toxicant exposure [96].
It is known that ROS have been implicated in the regula-
tion of ABCB1. However, there is still substantial controversy
about the association between ABCB1 expression and OS.
Conditions that generate ROS have been shown to increase
ABCB1 expression in the liver [97] and kidney [98]. Con-
versely, other studies have demonstrated decreased ABCB1
due to increased ROS levels in tumor spheroids [99]. The
actual amount of ROS seems to be essential in determining
what cellular effects are initiated. Thus, in conditions of OS,
ROS may function as an endothelial signal transduction
intermediate promoting cell survival, increasing ABCB1
expression. However, ROS may also lead to increased lipid
peroxidation, which is implicated in BBB disintegration, with
a consequent decrease in ABCB1 expression and activity. OS
is a cofactor in nearly every CNS disorders and there is sub-
stantial evidence that the accumulation of ROS can acutely
disrupt the BBB. Felix and Barrand demonstrated the
effect of OS on the expression of ABCB1 at BBB endothelium
[100]. They exposed primary cultured rat brain endothelial
cells to hydrogen peroxide, causing a concentration-
dependent increase in expression and activity of ABCB1.
A subsequent study by the same group proposed the
involvement of several signaling effectors including ERK1/
2, Akt, and JNK, which in turn activated nuclear factor-κB
(NF-κB). Consistent with these results, Hong et al. demon-
strated that ABCB1 expression was upregulated under con-
ditions of chronic OS-induced GSH depletion in rat brain
capillary endothelial cells [101]. These effects were reversed
by the ROS scavenger, N-acetylcysteine, suggesting that
depletion of GSH leads to elevated ROS, which induces
ABCB1 expression. ROS can play a crucial role in signal
transduction [102] through various transcriptional factors,
such as NF-κB and nuclear factor E2-related factor-2
(Nrf2). In turn, these transcription factors can regulate the
expression of ABC transporters. Nrf2 is a transcription fac-
tor that regulates the expression of proteins that protect
against OS. Nrf2 normally resides in the cytoplasm bound
to Kelch-like ECH-associated protein 1 (Keap1). Upon oxi-
dant/electrophile binding on Keap1, Nrf2 is released and
translocates to the nucleus where it binds to antioxidant
response elements, increasing expression of key players in
the antioxidant response, including genes that code for
proteins that produce GSH, reduce ROS, and metabolize
xenobiotics. Importantly, administering Nrf2 ligands is neu-
roprotective in animal models of neurological disorders,
such as cerebral ischemia, subarachnoid hemorrhage, spinal
cord injury, PD, and AD [103–107]. Wang et al. demon-
strated that Nrf2 activation with the isothiocyanate sulfo-
raphane (SFN) in vivo or in vitro increases expression and
transport activity of ABCB1 at the BBB. Dosing rats with
SFN increased ABCB1 expression in the brain capillaries
and decreased by 50% brain accumulation of the ABCB1
substrate, verapamil. No such effects were seen in the brain
capillaries from Nrf2-null mice, indicating Nrf2 dependence
[108]. Oxidative damage is a relative early event in the path-
ogenesis of AD. Several findings support the hypothesis that
Aβ interferes with oxidative phosphorylation, which results
in OS and apoptosis in brain cells [109, 110]. According to
the amyloid cascade hypothesis, AD results from the accu-
mulation of Aβ in the brain [1]. The neurovascular hypoth-
esis of Zlokovic et al. states that a critical pathological event
driving Aβ accumulation in the brain is the reduced
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clearance of Aβ from the brain across the BBB [111]. Over
the last 10 years, a new AD research field emerged with a
focus on ABC transporters at the BBB and in other cells of
the CNS. Lam et al. [112] were the first to demonstrate that
the potent and efficient efflux transporter ABCB1 is able to
transport Aβ. Pharmacological blockade of ABCB1 rapidly
decreased extracellular levels of Aβ secretion. They were
able to directly measure transport of Aβ peptides across
the plasma membranes of ABCB1-enriched vesicles and
showed that this phenomenon was both ATP- and
ABCB1-dependent. The transport of Aβ at the BBB is
bidirectional. As shown in Figure 1, the two main Aβ efflux
transporters include the low-density lipoprotein receptor-
related protein 1 (LRP-1) and ABCB1, and the receptor
for advanced glycation end-products (RAGE) is the main
Aβ influx transporter [14, 113].
As demonstrated by Hartz et al. [114], extracellular Aβ
first comes into contact with LRP-1 on the abluminal side
of the brain endothelial cell. This is followed by transport of
Aβ into the vascular lumen by ABCB1, or by a ABCB1-
independent pathway. Entry of circulating Aβ into the brain
is mediated by RAGE, but can also be restricted by ABCB1
[115]. The mode of interaction between Aβ and ABCB1 is
not clear yet. Previous studies raised two possibilities: (i)
ABCB1 could mediate Aβ transport directly or (ii) ABCB1
could interact with Aβ but does not transport it. In this case,
ABCB1may anchor Aβ on the plasma membrane and inhibit
uptake into the endothelial cells [116]. In pathological condi-
tions, as AD, it is possible to observe a reduction of ABCB1 at
the BBB, which is probably associated with the accumulation
of Aβ in the brain. As previously demonstrated by Loo and
Clarke [117], the ubiquitin-proteasome pathway is responsi-
ble, at least in part, for the regulation of ABCB1 trafficking,
localization, stability, and functions. In a recent work, Hartz
et al. [118] focused on the critical mechanistic steps involved
in the reduction of ABCB1 in AD. They investigated in the
brain capillaries if Aβ40 triggers ABCB1 ubiquitination,
internalization, and proteasome-dependent degradation
leading to reduction of ABCB1 expression and activity.
Indeed, experiments with microtubule and proteasomal
inhibitors confirmed that ABCB1 was internalized and
degraded by the proteasome. As the authors expected, Aβ40
activates the ubiquitin–proteasome system at the BBB, result-
ing in ABCB1 degradation and in a reduction of its expres-
sion and activity levels.
Moreover, it is possible to hypothesize that diminished
ABCB1 expression due to increasing age, genetic, or environ-
mental factors may lead to impaired Aβ clearance, followed
by the accelerated accumulation of intracerebral Aβ and
eventually the development of AD.
Cirrito et al. [14] provided the first evidence of a direct
link between BBB, ABCB1, and Aβ brain deposition. Using
Mdrla/b−/− double-knockout mice, the authors demonstrated
that brain clearance of Aβ was significantly lower compared
to that in control animals after intracerebroventricular
injection of Aβ. Then, the authors dosed transgenic hAPP-
overexpressing mice, a well-established AD model, with a
selective ABCB1 inhibitor and measured Aβ brain concen-
trations by microdialysis. As expected, Aβ levels in the brain

















Figure 1: Proposed components of the Aβ efflux and influx across the blood-brain barrier. The two main Aβ efflux transporters include the
low-density lipoprotein receptor-related protein 1 (LRP-1) and ABCB1, and the receptor for advanced glycation end-products (RAGE) is the
main Aβ influx transporter.
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untreated hAPP control mice. Moreover, isolated brain
capillaries from transgenic Tg2576 mice showed a 70%
decrease in ABCB1 transport activity and a 60% decrease
in ABCB1 protein expression compared to age-matched
wild-type mice [114]. Consistent with these in vivo studies,
a significant negative correlation exists between the densities
of senile plaque and ABCB1 levels in the brain capillaries of
patients with AD [119]. Interestingly, using 11C-verapamil
and positron emission tomography imaging, a clinical study
showed significant reduction in ABCB1 activity in AD
patients compared to cognitively normal subjects [120].
Another study detected 25% lower ABCB1 protein expres-
sion levels in hippocampal blood vessels in postmortem brain
samples fromAD patients than in samples from age-matched
nondemented patients [121]. Despite all these data support-
ing the involvement of decreased ABCB1 activity in Aβ accu-
mulation in AD, little is known about the mechanisms that
could initiate or sustain these transport deficiencies in disease
progression. Some studies pointed at Aβ accumulation itself
as a causative factor [122, 123]. Park et al. proved that Aβ
mediated ABCB1 downregulation in murine brain endothe-
lial cells by RAGE activation. These authors suggested that
activation of RAGE by Aβwould enhance NF-κB activity that
decreases ABCB1 expression [124]. It is possible that in the
early stages of the disease, accumulation of Aβ levels in the
brain capillary plasma membrane could directly impair
ABCB1 function, lead to Aβ accumulation, and reduce
ABCB1 expression. Hartz et al. [125] suggested that Aβ
contributes to the loss of BBB integrity that could be responsi-
ble for BBB dysfunction and cognitive decline and to the com-
promised integrity of both specific membrane transporters
and proteins of the tight junction complex. Altered BBB
homeostasis not only causes neuronal damage but also com-
promises Aβ clearance at theNVU, resulting in a vicious cycle
between Aβ accumulation and BBB dysfunction during AD
progression [126]. Although BBB disruption is often detected
in AD patients, it is not clear whether it is a specific feature of
AD. In this regard, further studies should be conceived to
define how BBB function is altered before AD onset and
during disease progression. A deeper understanding of how
BBB dysfunction is a cause or consequence in AD pathogene-
sis could allow the development of new therapeutic strategies
targeting BBB for this neurodegenerative disease.
In our opinion, also OS and neuroinflammation may play
a pivotal role in these transport deficiencies. The AD brain is
in a chronic proinflammatory state, and indeed, Aβ causes
inflammation in the brain through Toll-like receptor and
complement activation [127], and elevated levels of proin-
flammatory cytokines and acute phase proteins are localized
around Aβ plaques [128]. It was reported that ABCB1
downmodulates the function of dendritic cells, which are
considered to be crucial regulators of specific inflammatory
processes through the secretion of proinflammatory cyto-
kine, resulting in an impaired immune response. This find-
ing suggests a new physiological role for ABCB1 as an
immunomodulatory molecule and reveals a possible new
target for immunotherapy [129].
Oligomeric Aβ can also generate OS by producing the
lipid peroxidation product, 4-hydroxynonenal [130], and
through activation of NADPH oxidase, the superoxide-
producing enzyme, in microglia [131]. On the other hand,
inflammation and/or OS can themselves cause Aβ accumula-
tion in the brain, thus creating a vicious circle. Indeed, OS
upregulates proteins involved in Aβ production, such as
presenilin 1 [132].
Erickson et al. [133] speculated that downregulation of
BBB efflux transporters, as ABCB1, in AD may represent a
pathological consequence of prolonged vascular sequestra-
tion of Aβ as a result of sustained systemic oxidative and
inflammatory state. This possibility is supported by Hartz
et al. who showed in a transgenic model of AD that ABCB1
dysfunction at the BBB preceded symptoms of cognitive
impairment [114]. It is possible that aging would likely sensi-
tize an organism to inflammation and OS so that the thresh-
old required for Aβ efflux impairment is lowered [134]. Thus,
targeting intracellular signals that upregulate ABCB1 in the
early stages of AD has the potential to increase Aβ clearance
from the brain and reduce its accumulation.
5. What Therapeutic Perspectives?
Taking into account all these considerations, the concept that
restoring ABCB1 at the BBB could be a valid therapeutic
strategy to lower Aβ brain load, reduce cognitive decline,
delay onset, and slow progression of AD has to be critically
evaluated. The involvement of ABCB1 in the clearance of
Aβ was demonstrated by Brukmann et al. [135]. The authors
showed that the absence of ABCB1 results in a significant
disturbance of Aβ removal in a transgenic murine model of
AD (APP/PS1+/−−ABCB1), leading to an increased intrapar-
enchymal cerebral amyloid angiopathy. We need to consider
that if on the one hand, the BBB and ABCB1 are both
neuroprotective; on the other hand, they are substantial
obstacles to the delivery of drugs to the CNS. In this view, a
recent work suggested that the simultaneous administration
of verapamil, a known inhibitor of ABCB1 activity, and
berberine, a promising natural anti-inflammatory and
antioxidant compound, significantly potentiated their neuro-
protective effect on behavioral alterations, OS, mitochondrial
dysfunction, neuroinflammation, and histopathological
modifications in a streptozocin-induced rat model of spo-
radic dementia [136].
Thus, increased ABCB1 expression enhances neuropro-
tection, but at the expense of drug delivery; on the contrary,
reduced transporter activity decreases neuroprotection, but
provides opportunity to increase drug delivery to the CNS
[137]. This dual role of ABCB1 should be carefully consid-
ered in AD patients, because elderly patients often have a
combination of several chronic diseases and need proper
drug delivery.
For less than 10 years, the literature reported studies in
AD research to demonstrate the neuroprotective activity of
compounds acting on ABCB1. In 2009, Nishida et al. [138]
crossed AD transgenic (APPsw) model mice with α-tocoph-
erol transfer protein knock-out (Ttpa−/−) mice in which lipid
peroxidation in the brain was significantly increased. The
resulting double-mutant (Ttpa−/−APPsw) mice showed
increased Aβ deposits in the brain, which was ameliorated
6 Oxidative Medicine and Cellular Longevity
with α-tocopherol supplementation. Interestingly, the Aβ
generation in Ttpa−/−APPsw mouse brain was not
increased, but the authors considered that accumulated Aβ
in Ttpa−/−APPsw mouse brain was caused by these impaired
Aβ clearance. Aβ aggregation was accelerated in these mice
compared with wild-type, while LRP-1 and ABCB1 were
upregulated in the small vascular fraction of AD mouse
brains, probably to compensate their dysfunctions to
transport increased toxic substrates in the brain caused by
lipid peroxidation.
Moreover, in a transgenic mouse model of AD (human
amyloid precursor protein- (hAPP-) overexpressing mice;
Tg2576 strain), brain capillary ABCB1 expression and trans-
port activity were substantially reduced compared with wild-
type control mice, suggesting a mechanism by which Aβ
accumulates in the brain in AD. Treatment of 12-week-old
asymptomatic hAPP mice for 7 days with pregnenolone-
16α-carbonitrile to activate the nuclear receptor pregnane X
receptor (PXR) restored ABCB1 expression and transport
activity in the brain capillaries and significantly reduced the
brain Aβ levels compared with untreated control mice
[114]. PXR is activated by a number of drugs and dietary
constituents, and potent ligands for human PXR include
the antibiotic rifampin and the St. John’s wort (SJW) constit-
uent hyperforin [139]. In this regard, a clinical trial showed
that rifampin dosing lessened cognitive decline in patients
with AD over the 12-month treatment period [140]. The
mechanistic basis for this observation is not known, but
rifampicin activation of PXR leading to induction of ABCB1
in BBB is a likely possibility.
Another compound that modulates ABCB1 activity is
oleocanthal, a phenolic component of extravirgin olive oil.
The authors provided in vitro and in vivo evidences for the
potential of oleocanthal to enhance Aβ clearance from the
brain via upregulation of ABCB1 and LRP1 at the BBB. In
cultured mice brain endothelial cells, oleocanthal treatment
increased ABCB1 and LRP1 expression and activity. Brain
efflux index (BEI%) studies of 125I-Aβ40 showed that admin-
istration of oleocanthal extracted from extravirgin olive oil to
C57BL/6 wild-type mice enhanced 125I-Aβ40 clearance from
the brain and increased the BEI% from 62.0± 3.0% for
control mice to 79.9± 1.6% for oleocanthal-treated mice
[141]. In a further study, the same authors confirmed its
effect in the hippocampal parenchyma and microvessels of
TgSwDI mice, a transgenic model of AD [142].
In 2014, Brenn et al. [143] clarified the effect of SJWon the
accumulation of Aβ and ABCB1 expression in the brain. The
authors showed that long-term administration (60 and 120
days) of SJWextract (final hyperforin concentration 5%) leads
to a significant reduction of soluble Aβ1–42 (representing
mainly small oligomers and monomers) as well as Aβ40- and
Aβ42-positive plaque number and size (representing mainly
fibrillar and protofibrillar Aβ), while vascular ABCB1 expres-
sion was increased in the brains of double transgenic mice.
The expression of ABCB1 at the BBB is also regulated by
the vitamin D receptor (VDR). In 2011, Chow et al. [144]
showed that mice treated with the physiological ligand of
VDR, the 1α,25-dihydroxytitamin D [1,25(OH)2D3] had
lower accumulation of digoxin, an ABCB1 substrate.
Similarly, one year later Durk et al. [145] demonstrated
in vitro not only that rat brain endothelial cells (RBE4) and
human (hCMEC/D3) cerebral microvessels endothelial cells
incubated with 1,25(OH)2D3 showed an increase in ABCB1
expression but also that the treatment counteracted the brain
accumulation of Aβ. These findings were confirmed by a sec-
ond study conducted in 2014 by the same authors [146] with
two transgenic mouse models of AD, one at a preplaque for-
mation age (Tg2576) and the other at a plaque formation or
already formed age (TgCRND8). In this study, Durk et al.
showed that ABCB1 expression via VDR activation
decreased soluble Aβ and reduced plaque formation in
young TgCRND8 mice, improving also conditioned fear
memory. However, the treatment of old TgCRND8 mice
(after plaque formation), even if was able to decrease soluble
Aβ, it did not reduce the plaque burden. The study under-
lined not only the role of ABCB1 in AD pathogenesis but also
the importance of VDR on its regulation.
Another class of compounds identified as inducer for
ABCB1 activity was suggested by Manda et al. [147], which
demonstrated in LS-180 cells that fascalpsyn, a marine-
derived bis-indole alkaloid, along with its 4,5-difluoro,
induced a consistent fold increase in ABCB1 expression.
Moreover, these compounds showed an inhibitory activity
on acetylcholinestease (AChE), an enzyme strictly involved
in the neuronal loss observed in AD patients.
After a study where the activity of rivastigmine to
decrease Aβ accumulation was showed, in 2016, Mohamed
et al. [148] continued their work by crossing the transgenic
AD mouse model APPSWE with mdr1a/b knockout mice to
assess rivastigmine activity on three different levels of ABCB1
expression (APP+/mdr1+/+, APP+/mdr1+/−, and APP+/
mdr1−/−). The authors showed that the treatment with rivas-
tigmine increased the expression of ABCB1 and LRP1 in iso-
lated brain capillaries of APP+/mdr1+/+ and APP+/mdr1+/−.
Interestingly, ABCB1 deletion caused a significant increase
in parenchymal accumulation of Aβ40, but not Aβ42, when
compared to APP/mdr1 wild-type mice. This inverse correla-
tion between Aβ40 deposition and ABCB1 expression
suggests the importance of ABCB1 to maintain Aβ brain
homeostasis across the BBB.
The studies we have taken into consideration are summa-
rized in Table 1 and are all very interesting and encouraging,
but we believe that they need further investigation. Besides
many neuroprotective effects of these compounds, the induc-
tion of ABCB1 thus might enhance Aβ clearance from the
brain and thereby reduce the risk of developing AD. To test
this hypothesis, further studies are warranted to investigate
the effects of these compounds for example on animal behav-
ior and memory. However, these studies indicated that the
induction of ABCB1 is a promising therapeutic approach to
the treatment and/or prevention of neurodegenerative dis-
eases such as AD.
6. Conclusions
In summary, it is now clear that expression/activity of
ABCB1 at the BBB is strictly related toAβ clearance and even-
tually with AD progression. An understanding of transporter
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regulation is critical before we can determine to what extent
signaling can be manipulated to improve not only drug deliv-
ery to the CNS but also to enhance neuroprotection. Although
promising results in animal studies have been achieved, a bet-
ter understanding into the signaling cascade of this trans-
porter may result in a better understanding of AD etiology
and in the development of novel therapeutic strategies.
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